Akari Therapeutics plc ADR (0.01 USD)

AKTXNASDAQ • USD
6.71 USD
↗ 0.06 (0.90%)AT CLOSE (03:59 PM EST)
7.08
↗ 0.37 (5.51%)
POST MARKET (AS OF 04:10 PM EST)
Post Market
AS OF 04:10 PM EST
7.08
↗ 0.37 (5.51%)
🔴Market: CLOSED

Akari Therapeutics plc ADR (0.01 USD) (AKTX) trades at $7.17 per share. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation side, AKTX appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Nov 19, 2026.

Open?$6.65
High?$7.20
Low?$6.61
Prev. Close?$6.65
Volume?9.8K
Avg. Volume?40.9K
VWAP?$7.08
Rel. Volume?0.24x
Bid / Ask
Bid?$6.50 × 500
Ask?$8.88 × 100
Spread?$2.38
Midpoint?$7.69
Valuation & Ratios
Market Cap?15.3M
Shares Out?2.3M
P/E Ratio?N/A
P/B Ratio?0.88
EPS?-$12.87
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
Employees
5
Market Cap
15.2M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2012-12-07
Address
401 EAST JACKSON STREET
TAMPA, FL 33602
Phone: (929) 274-7510
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
73
Piotroski F-Score?0/9Weak
Altman Z-Score?-13.34Distress
Confidence?46%Low
Full Fundamental Analysis →
Short InterestLow
Short Interest?17.9K
Days to Cover?1.0
Avg Daily Volume44.5K
Settlement Date2026-10-30
Financial Health
Current Ratio?0.48Weak
Quick Ratio?0.48Weak
Cash Ratio?0.44Low
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.88CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.6CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-168.0%WEAK▾
ROA?
S&P
3
-80.4%WEAK▾
Cash Flow & Enterprise
FCF?$-12863000
Enterprise Value?$9.6M
Fundamentals ratios updated end of day